Precision BioSciences Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $218
- Today's High:
- $232.1
- Open Price:
- $229.8
- 52W Low:
- $0.682
- 52W High:
- $2.21
- Prev. Close:
- $229.95
- Volume:
- 18964
Company Statistics
- Market Cap.:
- $92.17 million
- Book Value:
- 0.355
- Revenue TTM:
- $30.56 million
- Operating Margin TTM:
- -319.02%
- Gross Profit TTM:
- $25.10 million
- Profit Margin:
- 0%
- Return on Assets TTM:
- -31.58%
- Return on Equity TTM:
- -197.62%
Company Profile
Precision BioSciences Inc had its IPO on 2019-03-28 under the ticker symbol DTIL.
The company operates in the Healthcare sector and Biotechnology industry. Precision BioSciences Inc has a staff strength of 197 employees.
Stock update
Shares of Precision BioSciences Inc opened at $229.8 at the start of the last trading session i.e. 2023-09-13.
The stocks traded within a range of $218 - $232.1, and closed at $218.65.
This is a -4.91% slip from the previous day's closing price.
A total volume of 18,964 shares were traded at the close of the day’s session.
In the last one week, shares of Precision BioSciences Inc have increased by +1.49%.
Precision BioSciences Inc's Key Ratios
Precision BioSciences Inc has a market cap of $92.17 million, indicating a price to book ratio of 1.6174 and a price to sales ratio of 6.3895.
In the last 12-months Precision BioSciences Inc’s revenue was $30.56 million with a gross profit of $25.10 million and an EBITDA of $-89712000. The EBITDA ratio measures Precision BioSciences Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Precision BioSciences Inc’s operating margin was -319.02% while its return on assets stood at -31.58% with a return of equity of -197.62%.
In Q1, Precision BioSciences Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 164.7%.
Precision BioSciences Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-0.93 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Precision BioSciences Inc’s profitability.
Precision BioSciences Inc stock is trading at a EV to sales ratio of 0.0292 and a EV to EBITDA ratio of 0.5036. Its price to sales ratio in the trailing 12-months stood at 6.3895.
Precision BioSciences Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $204.50 million
- Total Liabilities
- $46.86 million
- Operating Cash Flow
- $-721000.00
- Capital Expenditure
- $721000
- Dividend Payout Ratio
- 0%
Precision BioSciences Inc ended 2024 with $204.50 million in total assets and $0 in total liabilities. Its intangible assets were valued at $204.50 million while shareholder equity stood at $40.18 million.
Precision BioSciences Inc ended 2024 with $0 in deferred long-term liabilities, $46.86 million in other current liabilities, 1000.00 in common stock, $-453372000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $158.13 million and cash and short-term investments were $158.13 million. The company’s total short-term debt was $2,094,000 while long-term debt stood at $22.27 million.
Precision BioSciences Inc’s total current assets stands at $169.02 million while long-term investments were $8.16 million and short-term investments were $0. Its net receivables were $694000.00 compared to accounts payable of $701000.00 and inventory worth $0.
In 2024, Precision BioSciences Inc's operating cash flow was $-721000.00 while its capital expenditure stood at $721000.
Comparatively, Precision BioSciences Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $218.65
- 52-Week High
- $2.21
- 52-Week Low
- $0.682
- Analyst Target Price
- $6.29
Precision BioSciences Inc stock is currently trading at $218.65 per share. It touched a 52-week high of $2.21 and a 52-week low of $2.21. Analysts tracking the stock have a 12-month average target price of $6.29.
Its 50-day moving average was $209.05 and 200-day moving average was $209.48 The short ratio stood at 1.7 indicating a short percent outstanding of 0%.
Around 1508.3% of the company’s stock are held by insiders while 5062.6% are held by institutions.
Frequently Asked Questions About Precision BioSciences Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Precision BioSciences, Inc., a clinical stage gene editing company, develops ex vivo allogeneic chimeric antigen receptor (CAR) T immunotherapies and in vivo therapies for genetic and infectious diseases in the United States. The company offers ARCUS, a genome editing platform to cure genetic disorders. It also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, an azercabtagene zapreleucel, for the treatment of acute lymphoblastic leukemia and B-cell precursor acute lymphoblastic leukemia; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T cell candidate targeting B-cell maturation antigen for relapsed or refractory (R/R) multiple myeloma in combination with nirogacestat, a gamma secretase inhibitor. The company has development and commercial license agreements with Les Laboratoires Servier to develop allogeneic CAR T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; iECURE, Inc. to develop ARCUS-based gene-insertion therapies; and Novartis Pharma AG to discover and develop in vivo gene editing products. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.